FEATURED

Gilead Is Up 3.5% Today

There is a moment in every healthcare cycle where the market gets too focused on a single trial result and misses everything else building underneath it.

That is exactly where Gilead Sciences is right now.

GILD is up roughly 3.5% this morning after a Phase 3 HIV trial hit its key endpoints clean and Trodelvy won first-line approval for triple-negative breast cancer in both the U.S. and Europe. The FDA cleared Trodelvy for first-line treatment of advanced triple-negative breast cancer, both as a monotherapy and in combination with Merck’s Keytruda, with NCCN naming it a category 1 preferred option. HSBC upgraded the stock to Buy just yesterday, raising its price target to $155 from $133. The upgrade was pointed and specific: HSBC argued the market is too pessimistic about Gilead’s HIV franchise, assuming a steeper decline from generic competition than the underlying data supports. Long-acting HIV therapies, they argued, could offset much of that pressure through better patient adherence. Roughly 60% of HIV patients have suboptimal adherence, and more than 40% take fewer than 80% of prescribed doses. A once-weekly or once-monthly regimen changes that math entirely.

Then there is Trodelvy. The European Commission granted first-line monotherapy approval across all EU member states and the EEA. Regulators are also reviewing a supplemental filing to pair Trodelvy with Keytruda for PD-L1 positive disease across Europe. If that combination clears, Gilead’s oncology positioning moves from peripheral to central. Trodelvy alongside Merck’s Keytruda is not a side hustle. That is a potential backbone therapy on both sides of the Atlantic.

Gilead’s Q1 2026 results supported the upgrade thesis: revenue of $6.96 billion, beating estimates by roughly 1.5%. Adjusted operating margin came in at 46.9%, above expectations. Full-year product sales guidance was raised. Analysts maintain a Buy consensus with an average price target around $160. The stock is trading near $131-134 today. That gap between where it trades and where analysts think it belongs is the opportunity worth watching.

There is also the anito-cel angle. Gilead’s Arcellx acquisition brought in a CAR T-cell therapy for relapsed or refractory multiple myeloma that is currently under FDA review, with a decision expected by December 2026. Expectations for anito-cel remain modest despite a favorable efficacy and safety profile, largely because of limited long-term data compared with competing therapies. That is a low bar that could get cleared quietly. August 6 brings Q2 earnings. The catalysts are stacking.

Now Regeneron.

REGN reported Q1 2026 revenues up 19% to $3.6 billion. Non-GAAP EPS of $9.47 beat estimates. Dupixent global net sales grew 33% to $4.9 billion. EYLEA HD U.S. net sales surged 52% to $468 million. By the numbers, this is a company performing. And yet the stock is sitting roughly 21% below its 52-week high of $821.

The reason: pipeline.

Regeneron’s fianlimab and Libtayo combination failed to reach statistical significance for its primary endpoint of progression-free survival versus Merck’s Keytruda in a Phase 3 melanoma study reported on May 15. One trial. The market re-rated the entire oncology pipeline lower. HSBC cut its price target to $800 from $990 while keeping a Buy rating. Cantor Fitzgerald trimmed to $750 from $785. Multiple brokerages reduced price targets after the update.

Worth noting: a 5.1-month numeric improvement in median progression-free survival was observed for the high-dose fianlimab combination versus pembrolizumab, but it did not hit statistical significance. A separate head-to-head Phase 3 trial versus Opdualag is still ongoing. The story is not fully closed. But markets do not wait for nuance, and the re-rating happened fast.

The real debate with REGN is whether Dupixent can carry the business while oncology rebuilds. Dupixent keeps expanding. It now covers chronic spontaneous urticaria in children aged 2 to 11, allergic fungal rhinosinusitis, and continues adding indications globally. The drug is growing in the low-to-mid 30s percentage range annually. EYLEA HD is holding up better than feared despite biosimilar pressure, now comprising roughly 50% of the combined EYLEA franchise sales in the U.S.

There is also a structural tailwind coming: Regeneron will begin receiving its full share of Dupixent profits starting in Q3 2026, as a prior development balance clears. That is a real revenue unlock, and it is not fully priced into current estimates.

But the melanoma setback matters. It reset the growth multiple and created real uncertainty about the oncology path forward. Q2 earnings on July 30 will test whether Dupixent can keep the financial model intact while management rebuilds credibility. If it can, the stock at current levels may look cheap in hindsight. That is a 12-month thesis, not a near-term one.

Valuation is close but not identical. Gilead near $131-134 trades around 17.6x earnings with fresh Buy upgrades and an average analyst target around $160. Regeneron near $650 trades at roughly 16x earnings following its drawdown. Both are reasonably priced for large-cap biopharma. But Gilead has the near-term catalysts piling up: the Trodelvy EU combination filing pending, anito-cel FDA decision in December, Q2 earnings in August, and fresh institutional upgrades rather than ongoing cuts.

The call: Gilead is the stronger opportunity today. The HSBC upgrade is grounded in specific HIV adherence data. The Trodelvy approvals are real revenue events already happening. The long-acting HIV pipeline is more durable than what the current stock price implies. Regeneron remains a high-quality business with a world-class Dupixent franchise, and the Q3 Dupixent profit unlock is a real catalyst patient investors should not ignore. But in this window, the momentum, the catalysts, and analyst sentiment all point toward Gilead.